Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients

Abstract

BackgroundNeutropenic patients are at risk of abdominal complications and yet the incidence and impact of these complications on patients' morbidity and mortality have not been sufficiently evaluated. We aimed to assess a clinical rule for early detection of abdominal complications leading to death or transfer to intensive care in patients with chemotherapy-associated neutropenia. Design and MethodsThis observational multicenter study was carried out in seven German hematology-oncology departments. For inclusion, neutropenia of at least 5 consecutive days was required. Risk factors for "transfer to intensive care" and "death" were assessed by backward-stepwise binary logistic regression analyses. Chemotherapy-associated bowel syndrome was defined as a combination of fever (T ≥37.8 °C) and abdominal pain and/or lack of bowel movement for 72 hours or more. Five hundred and twenty-one neutropenic episodes were documented in 359 patients. ResultsThe incidence of chemotherapy-associated bowel syndrome was 126/359 (35%) in first episodes of neutropenia. Transfer to intensive care occurred in 41/359 (11%) and death occurred in 17/359 (5%) first episodes. Chemotherapy-associated bowel syndrome and duration of neutropenia were identified as risk factors for transfer to intensive care (P<0.001; OR 4.753; 95% CI 2.297-9.833, and P=0.003; OR 1.061/d; 95% CI 1.021-1.103). Chemotherapyassociated bowel syndrome and mitoxantrone administration were identified as risk factors for death (P=0.005; OR 4.611; 95% CI 1.573-13.515 and P=0.026; OR 3.628; 95% CI 1.169-11.256). ConclusionsThe occurrence of chemotherapy-associated bowel syndrome has a significant impact on patients' outcome. In future interventional clinical trials, this definition might be used as a selection criterion for early treatment of patients at risk of severe complications.Key words: neutropenia, chemotherapy-associated bowel syndrome, risk prediction.Citation: Vehreschild MJGT, Meißner AMK, Cornely OA, Maschmeyer G, Neumann S, von Lilienfeld-Toal M, Karthaus M, Wattad M, Staib P, Hellmich M, Christ H, and Vehreschild J-J. Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients.

Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients

“…The 14.2% incidence of CDI in this study compares to 5–33% rates reported among various neutropenic cancer patients including SCT recipients , albeit ours reported the cumulative incidence of CDI following several cycles of antineoplastic therapy including high‐dose myeloablative regimens delivered over approximately 1 year, as compared to shorter follow‐up periods in other reports .…”

Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota

“…1 Neutropenic colitis as its most severe complication has been associated with increased mortality. 2 Recent evidence suggests an even more complex role for chemotherapy-induced mucositis. Two independent groups were able to demonstrate in their respective mouse models that disruption of the mucous membranes' barrier function may enable a hitherto unknown mode of action of cytotoxic treatment.…”

Pharmacokinetics of Different Dosing Strategies of Oral Posaconazole in Patients with Compromised Gastrointestinal Function and Who Are at High Risk for Invasive Fungal Infection

“…Several studies have demonstrated that the bioavailability of posaconazole is significantly enhanced when given with food, particularly a high-fat meal (5,9), presumably because of an increase in dissolution. Patients at risk for IFD are often critically ill and may be unable to eat because of mucositis, severe nausea, neutropenic enterocolitis, or graft-versus-host disease (12,14,18). In these patients, absorption of posaconazole may be enhanced by dividing posaconazole doses or by administering the drug with a liquid nutritional supplement or acidic beverage (8,9).…”